Daniel N. Swisher Jr.

October 4, 2026

CORT Featured in Low-Beta Healthcare Stock List. Corcept Therapeutics was included in a recent list of low-beta healthcare stocks, highlighting its potential stability amid market concerns about interest rates. The company currently trades within its 52-week range, with a high trailing P/E ratio of 227.7. Analysts maintain an average price target of $141.00, reflecting a wide range of expectations for the stock's future performance.

October 15, 2026

Cerus to Present at 2026 AABB Annual Meeting. Cerus Corporation announced it will host a workshop and present abstracts at the upcoming 2026 AABB Annual Meeting. This event highlights the company's ongoing scientific engagement and clinical data sharing within the blood banking community. The announcement serves as a routine corporate update, providing context for the stock's current trading position near its support levels.

October 17, 2026

JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.